Programmed environmental illumination during autologous stem cell transplantation hospitalization for the treatment of multiple myeloma reduces severity of depression: A preliminary randomized controlled trial. by Valdimarsdottir, Heiðdís B et al.
UC San Diego
UC San Diego Previously Published Works
Title
Programmed environmental illumination during autologous stem cell transplantation 
hospitalization for the treatment of multiple myeloma reduces severity of depression: A 
preliminary randomized controlled trial.
Permalink
https://escholarship.org/uc/item/30s071b9
Journal
Cancer medicine, 7(9)
ISSN
2045-7634
Authors
Valdimarsdottir, Heiðdís B
Figueiro, Mariana G
Holden, William
et al.
Publication Date
2018-09-01
DOI
10.1002/cam4.1690
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Cancer Medicine. 2018;7:4345–4353.    |  4345wileyonlinelibrary.com/journal/cam4
Received: 9 May 2018 | Revised: 31 May 2018 | Accepted: 16 June 2018
DOI: 10.1002/cam4.1690
O R I G I N A L  R E S E A R C H
Programmed environmental illumination during autologous 
stem cell transplantation hospitalization for the treatment of 
multiple myeloma reduces severity of depression: A preliminary 
randomized controlled trial
Heiðdís B. Valdimarsdottir1,2  | Mariana G. Figueiro3 | William Holden2  |  
Susan Lutgendorf4 | Lisa M. Wu5  | Sonia Ancoli-Israel6 | Jason Chen2 |  
Ariella Hoffman-Peterson2 | Julia Granski2 | Nina Prescott2 | Alejandro Vega2 |  
Natalie Stern2 | Gary Winkel2 | William H. Redd2
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1Psychology, Reykjavik University, 
Reykjavik, Iceland
2Population Health Science and 
Policy, Icahn School of Medicine at Mount 
Sinai, New York City, New York
3Rensselaer Polytechnic Institute, Troy, 
New York
4Departments of Psychology and Brain 
Sciences, Obstetrics and Gynecology, and 
Urology, University of Iowa College of 
Liberal Arts and Sciences, Iowa City, Iowa
5Department of Medical Social 
Sciences, Northwestern University Feinberg 
School of Medicine, Chicago, Illinois
6Department of Psychiatry, University of 
California San Diego, La Jolla, California
Correspondence: Heiðdís B. Valdimarsdottir, 
Psychology, Reykjavik University, 
Mentaveg 1, 101 Reykjavik, Iceland 
(Heiddisb@ru.is).
Funding information
Division of Cancer Prevention, National 
Cancer Institute, Grant/Award Number: 
5R21CA209419-02
Abstract
Background: Over a third of multiple myeloma (MM) patients report clinical levels 
of depression during autologous stem cell transplant (ASCT) hospitalization. We 
report preliminary results from a randomized clinical trial investigating the effect of 
Programmed Environmental Illumination (PEI) of hospital rooms on depression.
Methods: Patients (N = 187) scheduled to receive an ASCT were assessed for eligibil-
ity. Those who met study eligibility criteria (n = 44) were randomly assigned to one of 
two PEI conditions involving delivery of either circadian active bright white light 
(BWL) or circadian inactive dim white light (DWL) throughout the room from 7 to 
10 am daily during hospitalization. Patients completed the Center for Epidemiological 
Studies Depression Scale (CES- D) prior to hospitalization, at days 2 and 7 post- 
transplant, and on the third day of engraftment.
Results: General linear model analyses revealed no difference between the groups in 
CES- D total score at baseline (P = 0.7859). A longitudinal linear mixed model analysis 
revealed a significant interaction between time of assessment and light condition 
[F(3,107) = 2.90; P = 0.0386; ɳ2 = 0.08)], indicating that PEI prevented the develop-
ment of depression during hospitalization, with effects reaching significance by the 
third day of engraftment. At the third day of engraftment, 68.4% of the participants in 
the DWL comparison condition met the criteria for clinically significant depression 
compared to 42.1% in the BWL condition.
Conclusion: These findings demonstrate that PEI using BWL during MM ASCT 
hospitalization is effective in reducing the development of depression. Future studies 
should examine the mechanisms whereby PEI improves depression.
K E Y W O R D S
Autologous Stem Cell Transplant, Bright Light Therapy, Circadian Rhythms, Multiple Myeloma
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1 |  INTRODUCTION
Autologous stem cell transplantation (ASCT) is the standard 
of care for newly diagnosed multiple myeloma (MM) patients 
determined able to withstand high- dose chemotherapy.1 
ASCT hospitalization is associated with high levels of both 
clinically diagnosed depression and self- reported depressive 
symptoms. This depression rises rapidly within the first week 
of hospitalization.2-4 One study found that while 7.8% of pa-
tients were clinically depressed during the week preceding 
hospitalization, 36.7% of patients were clinically depressed 
by day eight of hospitalization.4
Depression during ASCT hospitalization has been asso-
ciated with higher levels of post- traumatic stress disorder, 
lower quality of life, and enduring depression in the months 
and years following the transplant.5-7 Furthermore, clinical 
depression following ASCT predicts mortality;3,8 one study 
found that patients with major depression were three times 
more likely to die between 6 and 12 months following ASCT 
than those without major depression.8
Despite the high levels of depression during ASCT 
hospitalization and its adverse effects on psychological 
adjustment and mortality following ASCT, depression is 
underdiagnosed and undertreated among MM patients.9 
Moreover, current approaches to treating depression during 
ASCT hospitalization are limited. Pharmacological inter-
ventions, such as antidepressant medications, pose poten-
tial risks for interaction with specific drugs used during the 
ASCT and show little benefit over placebo.10 Although non-
pharmacological interventions such as cognitive behavioral 
therapy and exercise are effective in treating depression in 
cancer patients,11,12 they are extremely difficult to imple-
ment during ASCT hospitalization due to severe patient 
debility. Patients are rendered emotionally and physically 
exhausted; they have little interest in food, television, or 
even conversing with family members.
An easy to deliver, low- burden and inexpensive interven-
tion to alleviate depression is light therapy. Light therapy 
has been extensively used to treat seasonal affective disor-
der (SAD),13 and two recent meta- analyses showed that light 
therapy is effective in reducing nonseasonal depression as 
well.14,15 One hypothesized mechanism through which light 
therapy reduces depression involves the promotion of circa-
dian entrainment. Individuals suffering from depression ex-
hibit circadian disruption such as disturbances in the timing 
of sleep, melatonin, and cortisol rhythms.16 Cancer and its 
treatment are also associated with circadian disruption.17-19 
Given that light is one of the strongest zeitgebers for the cir-
cadian system, it is logical to hypothesize that a lighting sys-
tem designed to promote circadian entrainment in a hospital 
setting may reduce depressive symptoms.
Previous studies have administered bright white light 
(BWL) in various forms including handheld light boxes that 
deliver 2500 lux at the eye for 2 hours or 10 000 lux at the 
eye for 30 minutes to treat both seasonal and nonseasonal 
depression.13,15 The retinal mechanisms underlying circadian 
phototransduction (ie, how the retina converts light signals 
into electrical signals for the master clock and regulates cir-
cadian rhythms) have recently been elucidated. It is now well 
established that suppression of melatonin synthesis, a marker 
of the clock, is maximally sensitive to short- wavelength light 
with a peak around 460 nm.
Rea and colleagues proposed a mathematical model of 
human circadian phototransduction based upon published 
spectral sensitivity data,20,21 retinal neurophysiology, and 
neuroanatomy, including the operating characteristics 
of circadian phototransduction, ranging from response 
threshold to saturation.22-24 According to the Rea model, 
spectral irradiance at the cornea is first converted into cir-
cadian light (CLA) reflecting the spectral sensitivity of the 
circadian system that is then transformed into a circadian 
stimulus (CS). The CS value reflects the absolute sensitiv-
ity of the circadian system. Thus, CS is a measure of the 
effectiveness of retinal light to stimulate the human circa-
dian system, as measured by acute melatonin suppression, 
from threshold (CS = 0.1 or 10% melatonin suppression) 
to saturation (CS = 0.7, or 70% melatonin suppression). It 
is important to note that CLA and CS characterize the spec-
tral and absolute sensitivities of light- induced nocturnal 
melatonin suppression via the biological clock. CLA and 
CS are assumed to characterize the spectral and absolute 
sensitivities of the entire human circadian system because 
the suprachiasmatic nucleus (SCN) is the central link in 
a wide variety of daily regulatory functions such as hor-
mone production and sleep. For the purpose of this study, 
it was accepted that the spectral and absolute sensitivities 
of nocturnal melatonin suppression are similar to those 
controlling light- induced changes of circadian timing, or 
circadian entrainment.
Disrupted circadian rhythms co- occur with depression, 
both of which manifest through insomnia and early morn-
ing awakening. Indeed, these are common diagnostic cri-
teria for clinical depression.16 Sleep propensity rhythms 
closely associate with endogenous melatonin rhythms, and 
melatonin acts as both a soporific (sleep- promoting), and 
chronobiotic (circadian- entraining) agent. It is unclear, 
however, whether depressed individuals exhibit increased 
or decreased melatonin secretion, with studies supporting 
both notions.25 Interestingly, the antidepressant action of 
exogenous melatonin has been robustly demonstrated in 
animal studies.25-27 Agomelatine, a widely used antide-
pressant and structural derivative of melatonin, is a mela-
tonin receptor (MT1 & MT2) agonist as well as a serotonin 
receptor (5- HT2c) antagonist. Whether its antidepressant 
action can be attributed to a synergistic effect or to one 
of its receptor interactions independently is unknown.28 
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Melatonin’s relationship to depressed mood may instead 
be due to its chronobiotic activity. A healthy endogenous 
melatonin rhythm may be necessary, but not sufficient, to 
relieve depression with underlying circadian rhythm dis-
ruption. Melatonin, whether endogenous or exogenous, will 
synchronize the SCN; therefore, it is imperative to control 
its timing in order to entrain circadian rhythms. This can be 
accomplished using light therapy.
In the present study, we investigated the use of 
a novel ambient lighting intervention, Programmed 
Environmental Illumination (PEI) using freestanding light 
fixtures that delivered either Bright White Light (BWL) 
or Dim White Light (DWL) daily during hospitalization. 
The BWL delivered a CS ≥ 0.30 at the eye between 7 
and 10 am daily during hospitalization. A similar light-
ing system delivering a CS ≥ 0.30 showed a significant 
improvement in sleep, mood, and behavior in our field 
research with Alzheimer’s disease patients and other pop-
ulations.23,29-31 Relative to other light delivery systems, 
such as light boxes or light goggles, PEI requires no pa-
tient effort; the patient is able to remain passive in bed as 
the circadian stimulating light illuminates the room.
The present research investigates the impact of deliver-
ing circadian active light (CS = 0.3 BWL) from 7 to 10 am 
to MM patients during their ASCT hospital stay compared 
to patients receiving circadian inactive light (CS = 0.1, 
DWL). We hypothesized that participants exposed to the 
BWL would experience lower levels of depression during 
hospitalization than those exposed to the DWL. These anal-
yses are part of a larger program of research examining the 
effects of PEI in treating cancer- related fatigue during and 
following ASCT.
FIGURE 1  CONSORT: trial participant flow.
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2 |  METHODS
2.1 | Participants
Participant flow through the study is shown in Figure 1. Data 
were analyzed from 44 MM patients undergoing ASCT at 
Mount Sinai Hospital in New York, NY. Eligibility criteria 
included: first ASCT; 21 years of age or older; and English 
language proficiency. Exclusion criteria included: previous 
stem cell transplantation (autologous or allogeneic), preg-
nancy, eye diseases limiting the patient’s ability to process 
light (eg, untreated cataracts, severe glaucoma, macular 
degeneration, blindness, pupil dilation problems, or retina 
damage), secondary cancer diagnosis within the last 5 years, 
severe sleep disorders (eg, Narcolepsy), history of bipolar 
disorder or manic episodes (a contra- indication for light 
treatment), severe psychological impairment (eg, hospitali-
zation for depressive episode in the past 12 months), and/or 
previous use of light therapy to alleviate fatigue or depres-
sive symptoms. The Mt. Sinai Program for the Protection of 
Human Subjects approved the study.
2.2 | Procedure
Study personnel approached MM patients during their 
regular clinical visits. Study personnel described the 
study, obtained signed consent and administered the 
screening/eligibility measures questionnaires. Participants 
who qualified for the study were randomized using a 
block randomization table to either the bright white 
light (BWL; n = 23) or the dim white light comparison 
group (DWL; n = 21) group.32 Following randomization, 
an un- blinded study coordinator programmed each light 
fixture to the correct light condition prior to installation. 
All conditions were concealed from both the patient and 
the blinded study coordinators who administered the psy-
chological questionnaires and communicated with pa-
tients. Patients completed the Center for Epidemiological 
Studies Depression scale (CES-D) independently using a 
study iPad. Exceptions were made for patients experienc-
ing debilitating fatigue, in which case the surveys were 
administered orally. Blinded coordinators did not enter 
the hospital rooms while the light fixtures were turned on. 
Study participants completed CES-D at four timepoints: 
baseline, prior to hospitalization, day 2 post- transplant, 
day 7 post- transplant, and the third day (approximately 
day 14 post- transplant) of engraftment. Engraftment was 
defined as the period where the patient’s absolute neutro-
phil count is above 500 cells/mm3. After three consecu-
tive days above this value, the patient is considered fully 
engrafted; this is a marker of successful transplantation 
required for discharge.
2.3 | Programmed environmental 
illumination (PEI)
Acuity Brands provided freestanding light fixtures (Figure 2) 
delivering a CS value of 0.3 for the active, bright white light 
(BWL) condition (1300 lux at the eye level of the patients) 
and a CS of 0.1 for the dim white light (DWL) condition 
(90 lux at the eye level of the patients). Therefore, the BWL 
was designed to deliver circadian active light while the DWL 
was designed to deliver circadian inactive light. Ambient 
light illuminated the entire room. As is shown in Figure 3, 
both BWL (M = 0.339, SEM = 0.06) and DWL (M = 0.116, 
SEM = 0.055) were successful in delivering light at the in-
tended CS values. The light fixtures, previously programmed 
to the respective light condition, remained in the patients’ 
hospital rooms for the duration of hospitalization and were 
calibrated to turn on every morning from 7 to 10 am. During 
this time, patients were instructed to go about their normal 
activities, which could include leaving their hospital room. 
Based on prior research, 30 minutes a day of circadian ac-
tive bright white light was sufficient in reducing fatigue.33 
F I G U R E  2  Freestanding light fixture
   | 4349VALDIMARSDOTTIR eT AL.
A 3- hour time frame was chosen to ensure at least 30 min-
utes of exposure regardless of activity from 7 to 10 am. In 
order to verify that the correct dose of light was received, 
Daysimeters, light meters calibrated to measure CS, were 
placed behind the patient’s bed, on the light fixture, and on 
their chest, worn as a pendant by the patient during waking 
hours for the entire hospital stay. The Daysimeter is a re-
search tool manufactured by the Lighting Research Center at 
Rensselaer Polytechnic Institute; they are not commercially 
available.34 As hypothesized, those in the BWL condition re-
ceived light of a significantly (P < 0.0001) higher CS value 
than those in the DWL (Figure 3).
2.4 | Measures
Depressive symptoms were measured using the 20- item 
Center for Epidemiologic Studies Depression Scale (CES- 
D).35 A cutoff score of 16 or greater identifies individuals at 
risk for clinical depression. The CES- D has been shown to be 
a reliable measure for assessing the number, types, and dura-
tion of depressive symptoms across racial, gender, and age 
categories (Cronbach’s alpha ≥0.85). Concurrent validity by 
clinical and self- report criteria as well as substantial evidence 
of construct validity has been demonstrated. The CES- D 
was reliable in the present study (Cronbach’s alpha = 0.81, 
N = 44) and has been established as a valid and reliable 
measure of depression among cancer patients.36
2.5 | Statistical analysis
Using an intent- to- treat analysis and data from all randomized 
participants, the BWL condition was compared to a DWL 
condition. To determine equivalence between the BWL and 
DWL groups at baseline, a general linear model (GLM) was 
conducted. For the main analyses, a repeated- measures linear 
mixed model (LMM) was used to evaluate change in depres-
sive symptomatology over time using a random intercepts 
model. This approach makes use of all the data that each pa-
tient provided in parameter estimation and significance test-
ing, even if some of the repeated measures are missing.
Although the present research represented a trial effort to 
determine the effect size that would guide power consider-
ations in a larger study, we used the results of Redd et al33 to 
obtain an estimate of the effect size for the time by treatment 
condition interaction associated with the depression measure 
in the present pilot investigation. In the Redd et al33 study of 
fatigue in stem cell transplantation survivors, the interaction 
effect size was 0.98, indicating that a sample size of 60 pa-
tients would be sufficient to obtain a good estimate of effect 
size for power using the data from the present study.37 In the 
present report, 44 patients were evaluated as part of an in-
terim analysis.
3 |  RESULTS
3.1 | Participant characteristics
Table 1 summarizes the sample’s descriptive demographic 
and medical data, indicating that most study participants 
were male (59%), relatively well educated (65% reported 
a college or graduate degree), upper income (50% reported 
incomes above $80 000 per year), and either married or 
in a marriage equivalent (64%). The majority (59%) were 
Caucasian, and 27% self- identified as Black or African 
American. At the time of transplant, the majority of par-
ticipants (54%) had reached a very good partial response 
to treatment, were not on depression medications (91%), 
and were stage I (50%) on the International Staging System 
(ISS). Using the HCT comorbidity index, 59% had scores 
at 2 points or below. Importantly, there were no differences 
between the groups on demographic or medical variables 
(P < 0.2).
3.2 | Expectancy
The credibility/expectancy scale was administered at baseline 
for all participants and at day 2 post- transplant and third day of 
engraftment (both following patient exposure to conditions) for 
a subset of the participants. All data were analyzed for differ-
ences. There were no significant differences between the BWL 
and DWL groups at baseline [F(1,41) = 0.723; P = 0.400], day 
2 post- transplant [F(1,11) = 0.010; P = 0.923], and on the third 
day of engraftment [F(1,11) = 0.494; P = 0.497].
3.3 | Depressive symptoms
The GLM analysis of the CES- D total score revealed 
no significant difference in depressive symptoms be-
tween the BWL (n = 23, M = 9.26, SD = 7.03) and 
DWL (n = 21, M = 9.86, SD = 7.43) groups at baseline 
F I G U R E  3  Mean ± Standard Deviation of CS obtained from the 
bed Daysimeters values included are from the hours when the lighting 
intervention was programmed to be energized. As hypothesized, there 
was a significant difference in CS values received in the morning 
between the two groups
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(P = 0.7859). The repeated- measures LMM indicated that 
the main effect of time on CES- D total score was significant 
[F(3,110) = 13.35; P < 0.0001] . Specifically, there was an 
increase in depressive symptoms for all study participants 
during transplant hospitalization (Mean Baseline = 9.54; 
Mean Day 2—Post- Transplant = 12.09; Mean Day 7—Post- 
Transplant = 16.18; Mean Day 14—Engraftment = 18.97). 
The interaction of the time by treatment condition effect was 
significant [F(3,107) = 2.90; P = 0.0386], with a medium 
effect size (ɳ2 = 0.08). This result means that changes in de-
pression over time differed depending on whether the patient 
was exposed to either the DWL or BWL condition. A graphi-
cal plot of the interaction (Figure 4) illustrates how the BWL 
and DWL groups differed in their trajectories of depressive 
symptoms over the study period. Figure 4 shows a greater 
increase in depressive symptoms for patients in the DWL 
condition compared to patients in the BWL condition begin-
ning at day 7 post- transplant and peaking on the third day 
of engraftment. Additionally, Figure 4 shows that the mean 
levels of depression were below the clinical depression cutoff 
of 16 on the CES- D scale in the BWL group at all timepoints, 
while this was not the case in the DWL group.
3.4 | Clinical depression
At baseline, 28.6% and 17.4% of the participants in the 
DWL and BWL, respectively, were above the clinical 
depression cutoff of 16 on the CES- D. At day 7 post- 
transplant, about 40% of participants in both groups scored 
T A B L E  1  Patient demographic and medical variables
BWL DWL
n / (%) n / (%)
Gender (n = 44) n = 23 n = 21
Male 14 (61) 12 (57)
Female 9 (39) 9 (43)
Race/Ethnicity (n = 44) n = 23 n = 21
Black or 
African- American
9 (39) 3 (14)
White 12 (52) 14 (67)
Other 2 (9) 4 (19)
Marital status (n = 44) n = 23 n = 21
Not Married 10 (43) 6 (29)
Currently married/
marriage equivalent
13 (57) 15 (71)
Children at home (n = 40) n = 21 n = 19
No 15 (71) 8 (42)
Yes 6 (29) 11 (58)
Education (n = 43) n = 23 n = 20
High school or less 4 (17) 5 (25)
Partial college 2 (9) 4 (20)
College graduate 17 (74) 11 (55)
Employed (n = 44) n = 23 n = 21
No 13 (57) 12 (57)
Yes 10 (43) 9 (43)
Annual income (in dollars) 
(n = 40)
n = 20 n = 20
Below 80 000 8 (40) 12 (60)
Above 80 000 12 (60) 8 (40)
Pre- HCT disease status 
(n = 44)
n = 23 n = 21
No evidence of disease 0 (0) 0 (0)
Complete response 1 (4) 1 (5)
Near complete response 1 (4) 1 (5)
Very good partial 
response
14 (61) 10 (48)
Partial response 6 (26) 6 (28)
Stable disease 1 (4) 1 (5)
Progressive disease 0 (0) 2 (9)
HCT comorbidity index 
total score (n = 44)
n = 23 n = 21
0 4 (17) 4 (19)
1 2 (9) 1 (5)
2 8 (35) 7 (33)
3 4 (17) 4 (19)
4 0 (0) 1 (5)
5 1 (4) 2 (9)
(Continues)
BWL DWL
n / (%) n / (%)
6 1 (4) 1 (5)
7 2 (9) 1 (5)
8 1 (4) 0 (0)
Depression medication 
Pre- HCT
n = 23 n = 21
No 21 (91) 19 (90)
Yes 2 (9) 2 (10)
ISS stage n = 23 n = 21
1 13 (57) 9 (42)
2 1 (4) 5 (24)
3 1 (4) 1 (5)
Unspecified 8 (35) 6 (29)
Table reports tracked demographic and medical variables and their prevalence 
within the sample. All demographic information was gathered through self- report 
questionnaires. All medical information was gathered through medical chart 
screening, including a pretransplant physician assessment that included the HCT 
comorbidity score, ISS stage and status of disease. Chi- square analyses revealed 
no significant differences between the groups on any demographic or medical 
variables.
T A B L E  1  (Continued)
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above the clinical cutoff. However, at the third day of en-
graftment, 68.4% of participants in the DWL group scored 
above the clinical cutoff compared to 42.1% of the partici-
pants in the BWL group.
4 |  DISCUSSION
The present study examined the effectiveness of Programmed 
Environmental Illumination (PEI) using freestanding light 
fixtures in the hospital room delivering circadian active 
bright white light (BWL) from 7 to 10 am daily to reduce 
depressive symptoms during ASCT. PEI using BWL reduced 
the severity of depressive symptoms during hospitalization 
compared to circadian inactive dim white light (DWL). To 
our knowledge, this is the first study to show beneficial ef-
fects of PEI on depressive symptoms among MM patients 
undergoing ASCT.
The BWL and DWL groups differed in both their trajectory 
and final levels of depressive symptoms during hospitaliza-
tion. Mean levels of depressive symptoms increased sharply 
during the first week of hospitalization in both groups, then 
leveled off in the BWL group but continued to increase in 
the DWL condition until the third day of engraftment. Mean 
levels of depression were below the clinical depression cut-
off on the CES- D scale in the BWL group at all timepoints. 
However, the DWL group remained above the clinical cutoff 
beginning at day 7.
Depressive symptoms that met the CES- D clinical cut-
off criteria for depression showed a similar pattern. In both 
the BWL and the DWL groups, the proportion of patients 
meeting the clinical cutoff criteria increased from approxi-
mately 20% at baseline to approximately 40% at day 7 post- 
transplant. The proportion of patients meeting the depression 
cutoff criteria then continued to increase in the DWL group, 
but remained stable the BWL group with 68.4% and 42.1% 
meeting the depression cutoff criteria, respectively, at the 
third day of engraftment.
It is important to draw attention to the impact of PEI on 
depression in relation to how sick ASCT patients are during 
their hospitalization. As mentioned in the introduction, their 
exhaustion renders them able to do very little as their hos-
pitalization continues. Both patients and physicians attribute 
the hospitalization period with the highest degrees of distress, 
often viewing it as unmodifiable.38,39 The capability of PEI to 
prevent the worsening of depressive symptoms indicates real 
clinical benefit.
The discovery of a clinically significant benefit from PEI 
in the prevention of escalating depression adds to the grow-
ing literature demonstrating that BWL can effectively treat 
depressive symptoms in diverse populations.22,40-42 These 
results have the potential for major clinical implications as 
depressive symptoms during hospitalization affect not only 
patient quality of life5,7 but also increases their risk of subse-
quent morbidity and mortality.8
The findings may also have major implications for light-
ing in hospital rooms. Circadian active ambient light in the 
hospital room may not only reduce depressive symptoms but 
also other common symptoms of circadian disruption ex-
perienced by hospitalized cancer patients including fatigue 
F I G U R E  4  Mean ± Standard Deviation of CES-D scores obtained at each time point. As hypothesized, there was a significant difference in 
CES-D total scores by Day 14 post-transplant (day 3 of engraftment).
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and sleep disturbances. Our previous studies have shown that 
systematic light exposure delivering BWL by light book re-
duced fatigue and improved sleep efficiency among cancer 
survivors.33,43 We also found that PEI reduced depression 
in Alzheimer’s disease patients.22-24 Future studies should 
include comprehensive measures of common side effects 
during hospitalization as well as biological measures of cir-
cadian rhythm disruption to allow for examination of the 
mechanisms whereby light might impact these side effects.
The results reported here must be interpreted in the context 
of its limitations. First, the study is preliminary with a rela-
tively small sample size and is based on a larger program of 
research examining the effects of light to treat cancer- related 
fatigue. Second, the results presented here did not include 
post- hospitalization assessments of depressive symptoms. It is 
not yet known if PEI using BWL during hospitalization affects 
depressive symptoms during the post- transplant period. Third, 
the potential mechanisms underlying the effects of BWL on 
depressive symptoms were not examined; however, our pri-
mary hypothesis is that circadian entrainment plays a role.
The present findings demonstrate that an easy to deliver, 
low cost intervention alleviates depression during hospital-
ization for autologous stem cell transplantation. The light 
intervention may have application across a wide range of 
clinical settings and patient populations.
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